KFUM Kalmar and Bio Vitos Pharma enter into an agreement regarding a research study on Succifer

KFUM Kalmar and Bio Vitos Pharma have signed a collaboration agreement to conduct a research study entitled "Effect of oral iron succinate on iron deposits and exercise capacity in female athletes." This agreement marks an important step forward in strengthening the scientific evidence and investigating Succifer's potential benefits for female athletes.

The study will include 60 female athletes from Kalmar and will be conducted under the direction of Linnaeus University. Participants will be divided into three groups of 20 participants in each group to compare the effects of Succifer treatment, placebo and no treatment (control group). Each participant will undergo physical tests and blood tests before, during and after the study and commit to follow a given dietary instruction and keep daily diet and exercise diaries during the study.

- We are very pleased to have entered into this collaboration agreement with Bio Vitos Pharma to participate in this important research study. We are convinced that the study will provide valuable insight into how Succifer can affect iron stores and training capacity in female athletes, and we look forward to contributing to the scientific research in this area, says Jonas Sjöberg, Director of Sports at KFUM Kalmar.

- This collaboration is an important milestone for us in our endeavor to expand the scientific basis and our understanding of Succifer's effects on athletes. We are grateful for both KFUM Kalmar’s and Linnaeus University's commitment and look forward to working together to strengthen the scientific evidence and explore the potential of our product, says CEO Jesper Birgemo.

For further information, contact:

Bio Vitos Pharma AB (publ)

Jesper Birgemo, CEO

Tel: +46 (0) 70 895 39 34

About Bio Vitos Pharma AB

Bio Vitos Pharma develops, produces, and commercializes iron succinate for the treatment of iron deficiency within the parent company as well as a service for close-to-patient detection of hemolysis in blood samples within the framework of a wholly owned subsidiary, Hemcheck Management AB. The company is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB is the Certified Adviser to the company.